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A B S T R A C T
Hemoglobin (Hb)-based oxygen carriers (HBOC) are modified extracellular proteins, designed to replace or
augment the oxygen-carrying capacity of erythrocytes. However, clinical results have generally been dis-
appointing due to adverse side effects, in part linked to the intrinsic oxidative toxicity of Hb. Previously a redox-
active tyrosine residue was engineered into the Hb β subunit (βF41Y) to facilitate electron transfer between
endogenous antioxidants such as ascorbate and the oxidative ferryl heme species, converting the highly oxi-
dizing ferryl species into the less reactive ferric (met) form. We inserted different single tyrosine mutations into
the α and β subunits of Hb to determine if this effect of βF41Y was unique. Every mutation that was inserted
within electron transfer range of the protein surface and the heme increased the rate of ferryl reduction.
However, surprisingly, three of the mutations (βT84Y, αL91Y and βF85Y) also increased the rate of ascorbate
reduction of ferric(met) Hb to ferrous(oxy) Hb. The rate enhancement was most evident at ascorbate con-
centrations equivalent to that found in plasma (< 100 μM), suggesting that it might be of benefit in decreasing
oxidative stress in vivo. The most promising mutant (βT84Y) was stable with no increase in autoxidation or
heme loss. A decrease in membrane damage following Hb addition to HEK cells correlated with the ability of
βT84Y to maintain the protein in its oxygenated form. When PEGylated and injected into mice, βT84Y was
shown to have an increased vascular half time compared to wild type PEGylated Hb. βT84Y represents a new
class of mutations with the ability to enhance reduction of both ferryl and ferric Hb, and thus has potential to
decrease adverse side effects as one component of a final HBOC product.
1. Introduction
Hemoglobin (Hb) Based Oxygen Carriers (HBOC, colloquially
termed “blood substitutes”) have the potential to be transfused at high
dose in place of packed red blood cells to restore impaired oxygen
transport [1]. However, at lower doses HBOC products can be targeted
not as a red blood cell replacement, but as a product that can deliver
oxygen more efficiently to sites the red cell cannot reach, either due to
abnormalities of red cell deformability (e.g. sickle cell crisis), regional
tissue hypoxia (e.g. subarachnoid haemorrhage, stroke) or a disordered
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microvascular circulation that the red cell cannot traverse (as seen in
trauma, sepsis and other acute inflammatory states). When used in this
way as an “oxygen therapeutic”, HBOC products do not deliver bulk
oxygen, but instead facilitate oxygen transfer from the red cell. In effect
a high oxygen affinity HBOC is performing between the vasculature and
the hypoxic tissue, the same role that myoglobin (Mb) plays within the
muscle cell [2,3] in enhancing oxygen diffusion.
Whatever their proposed in vivo role, HBOCs have historically faced
issues in development due to adverse side effects caused by Hb toxicity.
Outside the red blood cell, Hb toxicity is in part due to nitric oxide
scavenging reactions [4], although it is possible to engineer decreased
nitric oxide scavenging properties, thereby decreasing the vasocon-
striction caused by extracellular Hb [5]. However, extracellular Hb also
has an intrinsic oxidative reactivity that damages cells, proteins, lipids
and DNA [6]. Additionally, free heme released from Hb acts as a Da-
mage Associated Molecule Pattern protein (DAMP) molecule which can
activate the immune system [7].
Maintaining Hb in its functional oxygen carrying ferrous state is key
to its function as an HBOC. Most HBOC as delivered contain a fraction
(≅5%) of Hb in the ferric state (metHb). The steady state level of me-
themoglobin is a function of the balance between its formation via the
autoxidation of oxyhemoglobin and the reduction of methemoglobin
via methemoglobin reductase systems. Inside the red blood cell the
enzyme methemoglobin reductase converts methemoglobin to oxyhe-
moglobin using the reducing power of NADH, although non-enzymatic
mechanisms can also contribute [8]. However, in the plasma this en-
zyme is not present. The reduction of HBOC is therefore powered by
plasma antioxidants, in particular ascorbate [9] Some regeneration of
the oxidized ascorbate is possible from intra-erythrocyte NADH via a
trans-plasma membrane reductase system. However, plasma ascorbate
levels are likely to be compromised in severe trauma and/or in humans
and animals such as guinea pigs that have lost the ability to synthesize
ascorbate. As a consequence, the ability to maintain the hemoglobin in
an HBOC in its functional oxygen carrying ferrous form varies with both
the HBOC itself, the animal model used and the level of trauma. Me-
themoglobin levels can therefore drop [10], stay the same [11], or in-
crease [9] following HBOC addition.
The metHb levels are also important as increasing metHb induces
oxidative stress in vivo by reacting with peroxides [12]. In the ferrous
state this creates ferryl iron; in the ferric state, both ferryl iron and
globin radicals are produced. Following peroxide addition to ferric
globins, ascorbate can quantitatively capture both the ferryl iron and
the free radical species [13]. However, kinetic limitations may result in
partial reduction and an increase in tissue oxidative damage. Using
recombinant tools it is possible to design a protein to be less oxidatively
reactive [14]. Tyrosine amino acids are able to act as redox mediators
by cycling between oxidized (radical) and reduced forms. Mb [15] and
the Hb α-subunit, but not the β-subunit [16] have electron transfer
pathways that are able to enhance the rate of ferryl reduction by plasma
antioxidants. These proteins have a high affinity saturable pathway.
Introducing such a pathway in the β-subunit in the homologous site
where one is present in the α-subunit (βF41Y) resulted in enhanced
ferryl reduction in tetrameric hemoglobin [16]. A range of mutations
was then introduced into a model system – Mb from the Sea Hare
(Aplysia fasciata), which lacks any tyrosine residues. A variety of phe-
nylalanine to tyrosine mutations were engineered with enhanced elec-
tron transfer pathways for ascorbate [17]. In the presence of ascorbate,
but not in its absence, these mutants had significantly decreased lipid
peroxidation activity compared to the wild type (WT) protein. A similar
effect was seen in the human βF41Y mutation. However, the rate
constant enhancement seen in the Aplysia mutations was orders of
magnitude greater than that seen following the human mutation. To
that end we engineered a range of new tyrosine mutations in the human
Hb α and β subunits to see if a similar large increase could be observed.
Surprisingly, we found that a subset of these mutations were also able
to facilitate the reduction of ferric iron to ferrous iron i.e. return ferryl
Hb to a fully functioning ferrous oxy/deoxy oxygen transport molecule.
As the ferric form of Hb is the most unstable, triggering heme loss and
protein degradation [18], we tested in vivo the mutant best able to
reduce ferric to ferrous (βT84Y) to see if these properties, once in-
corporated into a functioning HBOC, also enhanced vascular half-time.
2. Experimental
2.1. Protein preparation
The cloning, expression and purification of the Hb proteins for in
vitro studies was carried out as previously described [16] and the
proteins stored in the stable ferrous CO adduct form (HbCO). The
conversion of the stored ferrous CO adduct to the ferric (met), ferrous
(deoxy) and ferrous (oxy) were as in [19]. For enhanced purification for
cellular studies additional anion exchange and metal affinity steps were
introduced [20]. Scale up from shake flasks to fermentation growth was
required to produce enough protein for the animal studies. BL21-DE3 E.
coli cells carrying the adult or fetal Hb gene were cultivated in a 5 L
fermenter (BioStat A, Sartorius). Hb was grown according to methods
previously described [21,22] with minor modifications (glucose 70%
was used as carbon source and no acid feed was used). The production
of Hb was induced by adding IPTG (0.5mM) and δ-aminolevulinic acid
(2mM). Twelve hours after induction, the cells were harvested by
centrifugation. The harvested cells were lysed in buffer, Tris-HCl
50mM pH 8.5. Hb was purified using two-step ion exchange chroma-
tography, first a cation (Capto S) and then an anion (QHP) exchange.
Prior to the first step, the lysis buffer was exchanged to buffer sodium
phosphate (NaPi) 10mMpH 6.0. Hb was eluted in one step with NaPi
70mM pH 7.2. For the second step, the buffer was again exchanged to
buffer Tris-HCl 20mM pH 8.3. Hb was eluted with 10 column volume
linear gradient of NaCl from 0 to 100mM in NaPi 50mM pH 6.2. Just
before and after every purification step, the solutions of Hb were
bubbled with carbon monoxide (CO) to keep it in the oxidatively inert
CO-ligated form. The protein was then stored as the ferrous CO adduct
(HbCO) at − 80 °C.
2.2. Preparation of PEGylated hemoglobin
CO removal from stored Hb was carried out by illuminating CO
hemoglobin samples through a 75W Xenon to promote photolysis
under 100% oxygen flow. CO removal and substitution with oxygen
was confirmed by collecting absorption spectra. All concentrations of
Hb used were calculated as the tetrameric form, and were commonly
60 µM. Inositol hexabisphosphate (IHP) was added to the Hb solutions
to give the ratio of 1.2:1 (tetramer) and deoxygenated under helium
flow and gentle shaking for 4 h, at 20 °C. Iminothiolane (IMT) was
added to the Hb solutions to give the ratio of 80:1 (IMT:tetrameric Hb)
and after 6min maleimido-PEG added to give the ratio 12:1 (PEG:Hb
tetramer). The reactions was stopped with 5.3M lysine pH 6.5–7.5 after
34min and 0.9M cysteine after 46min. All solutions were prepared
using deoxygenated water and kept under nitrogen flow before addi-
tion. PEG-Hb solutions were dialyzed in phosphate buffered saline
(PBS) using Spectrum Hollow Fibers (50,000MW cut-off) to remove
unreacted PEG, IMT, lysine, cysteine and IHP. Endotoxin was removed
as described previously [23]. The level of endotoxin of the injected
samples was 34 EU/mL for the wild type and 11 EU/mL for βT84Y.
PEGylated Hb (PEG-Hb) samples were aliquoted into separate 5mL
vials, flash frozen in liquid nitrogen and stored at − 80 °C. prior to
shipping for animal studies. A new vial was separately thawed for each
animal to avoid protein degradation due to multiple freeze-thaw cycles.
2.3. Oxygen affinity measurements
Upon CO removal Hb solutions left overnight under helium flow in
the presence of the Hayashi reducing system before titrations [24]. The
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oxygen p50 and Hill coefficients were obtained by measuring optical
spectra after equilibration at varying pO2 gas mixtures as previously
described [25]. p50 was measured in 100mM Hepes, 1 mM EDTA,
100mM sodium chloride, 1.2 sodium phosphate, pH 7.0, 25 °C. The
fractional saturation was calculated fitting the data to a linear combi-
nation of oxy, deoxy and met Hb reference spectra.
2.4. Optical spectroscopy
Spectra were recorded on a Varian Cary 5E spectrophotometer. The
autoxidation (kobs min-1) of the rHb proteins was measured at 37 °C. For
each protein, the autoxidation (oxy to met conversion) was measured,
and the kinetic traces (577–630 nm) were analysed by single exponential
fittings to give kobs (min-1) values. Ferric reduction by ascorbate (met to
oxy conversion) was measured at 25 °C in 20mM NaPi, pH 7.20 and the
extent (%) of oxyHb formed calculated with reference to the 100% met
and oxyHb spectra of the relevant mutant. Heme loss from metHb
(1.7 μM) was measured in 20mM NaPi, pH 7.20, 37 °C by monitoring the
high to low spin state change when heme binds to 2 µM of the high
affinity heme scavenger hemopexin (Sigma, Aldrich). Spectra were taken
between 370 and 650 nm and the 417–599 nm difference fitted to a
single exponential decay. Ferryl hemoglobin was made by adding a 3:1
ratio of H2O2:metHb and waiting 10–15min until the spectral change
was complete (confirmed by the optical spectra). Trace catalase (1–5 nM)
was then added to remove unreacted H2O2. Ferryl reduction (ferryl to
met) by the reductant CP20 (deferiprone, 1,2-dimethyl-3-hydroxypyrid-
4-one) was analysed by double exponential fits of the time courses
(545–630 nm), assigning the faster phase to the α subunit and the slow
phase to the β subunit as described previously [16]. The autoreduction
rate constant at zero [CP20] was then subtracted from the rate and the
corrected data fit to Michaelis-Menton kinetics using non linear regres-
sion (errors are SEM from the curve fits). The SEM of the ratio Vmax /Km
was approximated from the respective SEM assuming the variables were
independent and using a first order Taylor expansion. Var(x/y) = x2/y2
* ( Var(x)/x2 +Var(y)/y2).
2.5. Cell assays
The metHb proteins were prepared as previously stated [19]. OxyHb
proteins were prepared by incubating HbCO under bright constant il-
lumination whilst gently blowing a stream of pure oxygen over the
surface of the liquid, and maintained on ice. Conversion to the oxyHb
form was monitored spectrally and was complete in about 30–45min.
Human Embryonic Kidney cells (HEK), was obtained from Lonza. Cells
were maintained in complete DMEM media (Lonza) in a humidified
atmosphere with 5% CO2 at 37 °C until confluent. For experiments to
test the effect of rHb on cells, cells were trypsinized, counted, plated
into 24 well plates and maintained until 70% confluent. Prior to all
treatments, cells were gently washed with warm phosphate buffered
saline and the media was replaced by serum and phenol free DMEM.
Cells were treated by adding 50 μM Hb (oxy or met), with or without
50 μM ascorbate to the media to a total volume of 250 μL. Cells were
placed a plate-reader (Tecan Infinite M200Pro) at 37 °C, 5% CO2 and
absorbance spectra 500–650 nm collected every 10min for 18 h. Kinetic
traces were produced by a three-point drop correction across the
577 nm oxy peak using 562 and 592 nm as reference wavelengths.
Cellular damage was assessed by measuring levels of lactate dehy-
drogenase (LDH) released into cellular media after 18 h of exposure to
the experimental treatment. The LDH assay (Sigma, Aldrich) was per-
formed according to manufacturer's instructions. The absorbance at two
wavelengths (450 and 650 nm) was obtained using a Tecan Infinite
M200Pro plate reader and both values were used to calculate levels of
LDH.
2.6. Animal studies
Following endotoxin removal, the PEG-Hb was lablelled with a
Cyanine5 dye NHS ester (Cy5-NHS; Cy5 for short) red fluorescent dye
(Lumiprobe, Germany). The pH of the PEG-Hb solution was adjusted to
8.5 with 400 μL of 0.1M NaHCO3 in an aliquot of 0.8mL. Next, 1 mg
Cy5 was dissolved in 200 μL dimethyl sulfoxide (DMSO, Sigma-Aldrich,
Germany). Subsequently, 1000 μL of PEG-Hb solution and 200 μL Cy5
solution was stirred and mixed at 400 rpm for 5 h at room temperature.
The resultant reaction mixture was purified to remove unreacted Cy5
using Size Exclusion Chromatography (SEC) in a NAP 10 column (GE
Life Sciences, Marlborough, MA, USA) for cleaning in two steps
(1000 μL and 200 μL, each) using the eluent physiological saline and
was collected as in a volume of 1200 μL. For further purification details
and characterization see Supplementary Fig. S1.
Animals were obtained from Charles River GmbH, Germany. NU
(NCr)-Foxn1nu/nu nude mice (n=5 per group, mixed gender, body
weight of 23–33 g) were allowed free access to food and water and
maintained under temperature, humidity, and light-controlled condi-
tions. All procedures were conducted in accordance with the ARRIVE
guidelines and the guidelines set forth by the European Communities
Council Directive (86/609 EEC) and approved by the Animal Care and
Use Committee of the IEM and the Semmelweis University (XIV-I-001/
29–7/2012). In the fluorescent whole-body imaging experiments, the
animal was initially anesthetized by Medetomidine (1mg/kgbw)
+Ketamine (100mg/kgbdw). Anesthesia was maintained using con-
tinuous inhalation of 2% isofluorane in medical grade oxygen gas.
While being scanned, the animal was placed on heating mat to maintain
the rectal temperature at 37.5 °C.
The whole-body biodistribution of Cy5-labeled PEG-Hb was mea-
sured in vivo at pre-injection and at different post-injection time points
(0, 1, 2, 4, 8, 24 h). Anesthetised mice were infused by top-loading via
the tail vein at a rate of 0.2 mL/min [4]. Animals involved in these
studies showed no signs of any manifest cardio-respiratory distress.
Sample selection (control, αV1M βV1M or test αV1M βV1M βT84Y)
was randomised and blind to those doing the study and analysis. Before
scanning, 0.1mL 1mg/mL Cy5 dissolved in saline was administered to
control mice via the tail vein, while treated animals got the same
amount of Cy5 dye in the form of Cy5-labeled PEG-Hb dissolved in
saline; the PEG-Hb used was 2.4 mM heme (3.84%) for αV1M βV1M
and 2.2mM (3.52%) for αV1M βV1M βT84Y. The animals were
scanned in two dedicated (prone and supine) positions with the com-
bination of a 630 nm light source and a 725 nm long-pass emission filter
for detection using a FOBI™ whole-body imager (Neoscience Ltd.,
Suwon City, Rep. Korea) at 1392×1040 pixel detector and 24 bit in-
tensity resolution. The exposure time was 1000ms per image with gain
level 1. Prior to fluorescence scanning, background images were re-
gistered in the same position using white light illumination
(400–800 nm) without applying any emission filter for detection. In
these cases, the exposure time was 200ms with gain level 1.
The blood level of labeled PEG-Hb and free Cy5 was measured by
smearing one drop of 100 μL blood freshly drawn the from the tail vein
onto the white plastic surface of a standardized balance plastic sample
holder (4 cm2). After a calibration measurement of the sample holder's
autofluorescence, the same holder with the thin blood film was put into
the FOBI optical imaging system and imaged with integration time of
1000ms and gain level 1. This procedure allowed for repetitive mea-
surements of blood levels of Lumiprobe Cy5 dye either in its free form
(control) or bound to PEG-Hb throughout a period of 24 h. Lumiprobe
Cy5 NIR fluorescence intensity was normalized to the pre-injection
level (i.e. autofluorescence). Following the last imaging time point
(24 h) whole-body saline perfusion was applied for 6min in order to
clear blood from the organ tissues. Subsequently, organs were removed
and their ex vivo fluorescent images taken with 1000ms exposure and
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gain level 1. Mice were terminally anesthetised by the dedicated ve-
terinary use euthanasia drug Euthasol® (ad us. vet. injection).
3. Results
Fig. 1 illustrates the location of the novel mutations introduced into
the human Hb α and β subunits. Table 1 describes the rationale for the
design of each mutation. All the engineered mutations could readily be
grown in shake flasks, purified and converted into the met, deoxy, oxy
and CO forms. In general (Table 2), introducing tyrosine residues led to
only minor (1–2 nm) differences from the optical absorbance peaks seen
in WT Hb. Some larger changes were seen in the visible region in the
metHb spectra. This is not unexpected as these are broad peaks and
sensitive to the heme iron spin state, which is pH dependent; a small
L91 
Alpha chain 
F71 
L96 
K66 
T84 
F85 
F41 
Beta chain Fig. 1. The three dimensional α- and β-chainstructures of HbA. Illustrating the position of the
novel mutations introduced. Structure file 2DN2
from the Protein Data Bank (www.pdb.org/pdb) was
used to generate the figure. Heme and proximal his-
tidine is in red (stick), sites of mutations are in green,
orange, pink or white (spacefill).
Table 1
Rationale for design of mutation.
Mutation Rationale for design
WT –
βF41Y Equivalent to Y42 in α subunit of Hb and F42Y in Aplysia (Mb); both natural (α) and introduced (Aplysia) mutations have been shown to enhance electron
transfer rates from external reductants to ferryl heme [15–17]
βK66Y A new surface exposed Tyrosine introduced on the distal side of heme pocket (all others are on the proximal side)
βF71Y A new Tyrosine introduced at the back of the heme pocket that is not surface exposed but within electron transfer distance of the surface (a control as to
whether surface exposure is necessary for enhanced reduction of ferryl heme).
βT84Y A new Tyrosine introduced at the back of the heme pocket that is surface exposed
βF85Y A new Tyrosine introduced at the back of the heme pocket that is surface exposed, but with a longer distance to heme edge (~ 10 Å)
αL91Y Position equivalent to F98Y in Aplysia Mb (a mutation that showed much faster electron transfer to ferryl heme even than that seen in WT α Hb [17]). An
attempt to see if the already fast reduction of ferryl heme in α Hb can be accelerated.
βL96Y Equivalent to F98Y in Aplysia Mb but now positioned with respect to β heme subunit.
βL91E/βL96Y The addition of L91E is in a position to stabilize L96Y deprotonation through H-bonding and hence accelerate the ferryl heme reduction rate (forming a
similar role to that attributed to E94 in Aplysia [17]).
αL91Y/βT84Y Combining mutations to test for a synergy of effects on ferric reducibility
αV1M βV1M Prevent extended N terminal length due to deficiency of methionine cleavage in E.coli. A standard tool used in preparing recombinant Hb for large scale
production by fermentation required for animal trials [22].
αV1M/βV1M βT85Y Combining mutations to enable test of enhanced reducibility in animal models
Table 2
Optical and oxygen binding properties of mutant proteins. The wavelength peaks of the optical bands in the visible (alpha/beta peaks) and Soret (gamma peak)
for the met, deoxy, oxy, and carbonmonoxy species following the introduction of new tyrosine residues into HbA. Conditions: sodium phosphate (20mM, pH 7.20);
T= 25 °C; [heme]= 10 μM. Oxygen affinities were measured at 100mM HEPES, 100mM sodium chloride, 1.2 mM sodium phosphate, 1mM EDTA, pH 7.0,
T= 25 °C.
Mutant WT βF41Y βK66Y βF71Y βT84Y βF85Y αL91Y βL96Y βL91E/βL96Y
MetHb
alpha 577 579 567 579 579 578 581 573 583
beta 540 541 537 541 542 542 536 540 542
gamma 407 407 413 407 407 407 407 407 407.5
DeoxyHb
alpha 582 584 587 584 583 583 583 584 584
beta 557 556 560 557 553 556 556 557 557
gamma 431 431 429 431 431 431 431 431 431
OxyHb
alpha 577 577 577 577 577 577 577 577.5 577.5
beta 542.5 543 543 543 543 543.5 544 543.5 543.5
gamma 417 417 417 417 417 416.5 417 417 416.5
HbCO
alpha 570 570 571 570 570 571 572 571 571
beta 541 541 541 540 539 541 542 540 542
gamma 419 419 421 419 420 419 420 420 420
p50 (torr) 5.21 ± 0.07 8.89 ± 0.51 1.17 ± 0.10 2.82 ± 0.37 7.16 ± 0.37 5.12 ± 0.17 14.91 ± 0.60 3.67 ± 0.60 9.63 ± 0.35
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change in the pK of the ferric heme would therefore lead to minor
changes in peak position. The one notable exception is βK66Y, which
does show larger changes in the deoxy and (especially) met forms. In
particular the significant red shift in the Soret peak (407–413 nm)
suggests that a large fraction of the ferric heme in the met form is low
spin at neutral pH, given that low spin complexes have red shifted Soret
peaks e.g. cyanide at 419 nm and azide at 417 nm [26]. This was con-
firmed by low temperature EPR spectroscopy which showed a large fall
in the g=6 high spin metHb signal in βK66Y compared to WT. All
mutants were able to reversibly bind oxygen, although the binding af-
finity differed from WT in some cases. The most striking difference was
the high affinity of the βK66Y mutant and the low affinity of αL91Y and
βL91E/βL96Y.
The initial goal was to determine if it was possible to enhance the
reduction rate of ferryl heme to metHb in recombinant human Hb [16]
by the orders of magnitude possible to achieve in Aplysia Mb [17]. The
hydroxypyridinone reductant CP20 has been shown to have a fast high
affinity rate of electron transfer to ferryl heme in the α subunit that is
saturated at low reduction concentration. In the β subunit the rate is
slower and low affinity, i.e. it is either linear with or saturates only at
very high reductant concentrations [16]. Fig. 2 shows the reduction of
ferryl Hb as a function of the concentration of CP20 in selected mutants:
WT (WT); a mutant with a tyrosine in the homologous position in the
subunit as the alpha subunit (βF41Y); and a mutant with a tyrosine in
an “unphysiological” position in the β subunit, but still surface exposed
and close to the heme (βT84Y) All three proteins have the equivalent
tyrosine in the α subunit (Y42) and all show a fast high affinity rate of
reduction of the ferryl heme in the α subunit by CP20. In contrast, only
the mutations with inserted tyrosine residues in the β subunit show a
clearly defined high affinity saturable rate in this subunit.
Table 3 quantifies the kinetic parameters for a number of the new
tyrosine mutations. In most cases inserting tyrosines into the β subunit
(βF41Y, βT84Y, βL91E/βL96Y) has only small effects on the reduction
of the ferryl heme in the α subunit compared to WT. Small increases in
Vmax are compensated by increases in Km, meaning that the calculated
second order rate constant for heme reduction Vmax /Km remains largely
unchanged (4–12×10-3 μM-1 min-1). Interestingly the addition of a
second tyrosine near the α heme (αL91Y) had only minimal or negative
effects, suggesting a limitation for heme reduction that is independent
of the pathway of electrons arriving at the physiological tyrosine
electron donor (αY42). In contrast, inserting a tyrosine residue close to
the β heme (where none is normally present) increases both the Vmax
and lowers the Km for ferryl heme reduction in this subunit. This results
in a ten-fold increase in Vmax /Km (from 0.07 in WT to 0.6–1.2×10-3
μM-1 min-1 depending on the mutant). The precise position of the tyr-
osine seems relatively unimportant; “unphysiological” positions are at
least as effective as inserting the tyrosine at the homologous site to that
in the α subunit (βF41Y). Unsurprisingly, the insertion of a tyrosine
near the α heme (αL91Y) did not create a high affinity route for elec-
tron transfer to the β heme. One mutant (βK66Y) showed apparently
Fig. 2. Concentration dependence of ferryl reduction rate. The rate con-
stants for the ferryl reduction of selected mutants by the reductant CP20: WT
(O); βF41Y (■);. βT84Y (▲). Conditions: 20mM NaPi, pH 7.20; T=25 °C;
[heme]=10 µM. Upper graph shows the high and low affinity α subunit rates.
Lower graph shows the slower β subunit rates, and illustrates the lack of a high
affinity rate in the WT β subunit lacking a surface exposed tyrosine residue.
Table 3
Kinetic parameters for ferryl reduction rates of mutants. Data taken from the conditions of Fig. 3 varying [CP20] (eleven concentrations from 5 to 1000 μM).
Errors are SEM from non linear curve fitting and so not relevant for the single point value in the absence of CP20 (autoreduction rate; Auto.).
α subunit β subunit
Auto. (min -1) Vmax (min-1) Km (μM) Vmax/Km (μM-1 min-1) × 10-3 Auto. (min -1) Vmax (min-1) Km (μM) Vmax/Km (μM-1 min-1) × 10-3
WT 0.057 0.33 ± 0.01 27.9 ± 3.1 11.8 ± 1.4 0.011 0.012 ± 0.000 179.0 ± 18.1 0.067 ± 0.007
βF41Y 0.081 0.48 ± 0.01 67.2 ± 6.1 7.1 ± 0.7 0.022 0.069 ± 0.002 61.7 ± 6.0 1.11 ± 0.34
βK66Y 0.61 2.28 ± 0.06 22.7 ± 2.5 100 ± 11 0.264 1.38 ± 0.04 94.6 ± 9.3 14.6 ± 1.5
βT84Y 0.086 0.51 ± 0.01 48.7 ± 3.2 10.4 ± 0.7 0.008 0.024 ± 0.001 19.7 ± 1.9 1.22 ± 0.13
αL91Y 0.037 0.50 ± 0.01 134.6 ± 7.9 3.7 ± 0.2 0.016 0.043 ± 0.002 356.7 ± 21.6 0.12 ± 0.01
βL91E/βL96Y 0.016 0.72 ± 0.04 76.0 ± 13.1 9.5 ± 1.7 0.045 0.081 ± 0.008 137.0 ± 39.1 0.59 ± 0.18
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much larger rates of ferryl to met conversion in both the α and β
subunits. However, on closer inspection the final spectrum formed was
significantly different to the original met spectrum confirming de-
gradative events other than simple reduction were occurring in this
mutant [27].
A comparison was then made of ferryl heme reduction using phy-
siological levels of the plasma reductant, ascorbate (Fig. 3). After one
minute all mutants with tyrosine insertions showed a significantly
higher metHb formation than WT. However, neither using CP20
(Table 3) nor ascorbate (Fig. 3) do the rates of α or β ferryl heme re-
duction approximate the thousand-fold increase seen in some Aplysia
Mb mutants [17].
Although metHb is less oxidatively damaging than ferryl Hb, it is
not functional in oxygen transport and can be readily converted back to
ferryl by peroxides, a process that additionally forms reactive protein-
bound free radicals. It would therefore be beneficial for an extracellular
HBOC to be further reduced from ferric metHb to ferrous oxyHb. In the
plasma only ascorbate has the reducing power to effect this conversion.
The reaction is biphasic with the faster reaction rate generally
attributed to reduction of the β subunit [28]. However, at physiological
levels of reductant, even in this subunit metHb conversion to oxyHb is a
slow process taking hours to reach completion in native Hb. We
therefore tested the ability of our mutants to accelerate met reduction
to oxyHb. Fig. 4 shows a significant increase in the rate of oxyHb for-
mation in βT84Y compared to WT. Fig. 5 compares the reduction of a
variety of mutants by physiologically plausible (100 μM) levels of
plasma ascorbate. WT MetHb is reduced to 20% oxyHb under these
conditions. Some mutants (βT84Y; βF85Y; αL91Y) show significant
increases compared to WT with over 50% metHb to oxyHb conversion
whereas others (βF41Y; βK66Y) show decreases with less than 10%
reduction. In a few mutants (βF71Y; βL91E/βL96Y) there is only a re-
latively small, if any, observable difference. Interestingly there is no
correlation between how fast the ferryl Hb form of a mutant can re-
duced by ascorbate with how fast the metHb formed can be further
reduced to oxyHb (Fig. 5, inset).
NADH and glutathione showed similar direct nonenzymatic rates of
metHb reduction in WT compared to ascorbate at the same (30 μM)
concentration after 60min incubation. However, there was no increase
Fig. 3. Ascorbate reduction of ferryl heme in re-
combinant Hb mutants. The % of metHb formed
after one minute incubation of ferryl Hb with 30 µM
ascorbate (mean ± SD, n= 3). The % metHb formed
was calculated from the ∆abs.545–650 nm as a per-
centage of the value of ∆abs.545–630 nm for the full
100% ferryl to met conversion. Conditions: sodium
phosphate (20mM, pH 7.20); temperature= 25 °C;
[heme]=10 µM.
Fig. 4. Enhanced rate of ascorbate
reduction of ferric heme in βT84Y.
Left. Graph to show the rate of formation
of oxyHb following ascorbate addition to
metHb for WT and βT84Y mutant. The
wavelength pair of 577–630 nm was
used to monitor met to oxy formation.
Right. Graph showing the spectra after
t=360min (wt= long dashed line,
βT84Y= short dashed line) compared
to the initial t=0min 100% met spec-
trum (solid black line). Conditions:
buffer = sodium phosphate (20mM, pH
7.20); T=25 °C; [heme]=4.4 µM;
[ascorbate]=100 μM added at t=0.
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in oxyHb formation in the βT84Y mutant (Mean %oxyHb ± SD, n=3:
glutathione WT 13.1 ± 0.9, βT84Y 9.6 ± 0.5; NADH: WT
12.4 ± 3.8, βT84Y 13.7 ± 0.5).
A closer examination of the rate of oxyHb formation at different
ascorbate concentrations (Fig. 6), reveals distinct biphasic kinetics. The
faster rate has previously been attributed to preferential reduction of
the β subunit [28,29]. This rate is essentially ascorbate concentration
independent (Fig. 6a) at sub mM [ascorbate]. It is this rate that differs
between mutants (Fig. 6b) being most increased in the βTyr84 mutant
and essentially absent in a Hb lacking the β subunit (fetal Hb). The
slower – ascorbate concentration dependent – second order rate is un-
affected by the addition of new tyrosine residues to the α or β subunit;
it is also identical in WT adult and fetal Hb (Table 4).
Combining mutations in the α and β subunits that enhance ascor-
bate reducibility did not have an additional beneficial effect (Table 5).
Crucially the most readily reducible mutant (βT84Y) did not lead to
increased rates of autoxidation or heme loss from the ferric from of the
protein and this mutant was therefore taken forward for further cellular
and animal studies. In order to prepare a more homogenous re-
combinant product for cellular and animal trials, the N-terminal valine
deletion was produced [22,30,31]. In both control and the mutant alike
this led to a decrease in ascorbate reducibility, but the distinction be-
tween the two was still evident (Table 5). The V1M mutation showed a
small decrease in oxygen affinity (p50=5.66 ± 0.26 Torr compared
to WT of 5.21 ± 0.07) but had no negative effect on autoxidation or
heme loss (Table 5).
The stability and oxidative reactivity of the ferrous form βT84Y was
compared to WT following addition to HEK cells. Phenol red free
DMEM media was used during the Hb stability and Hb-induced cell
damage studies as phenol has the ability to reduce higher oxidation
states of Hb and interferes with spectrophotometric assays. Hb was
added to cells in both the oxy and met forms and in the presence and
absence of ascorbate (Fig. 7). Following incubation with cells at 37 °C,
oxyHb was converted primarily to metHb, presumably driven by au-
toxidation. In contrast, metHb was partially converted to oxyHb driven
by the reducing power of the cell and/or the addition of 100 μM as-
corbate to the media. The value of oxyHb reached a steady state after
3–4 h. In all cases the steady state oxyHb was higher in the βT84Y
mutant than in WT Hb. The level of oxyHb remaining after 200min
negatively correlated with cell damage at 24 h as indicted by a decrease
in the release of lactate dehydrogenase, suggesting that the ability of
the βT84Y mutation to maintain higher levels of ferrous Hb was pro-
tective.
The effect of the βT84Y mutation on in vivo vascular retention time
of a HBOC was tested in a mouse top-load model. First the control
(αV1M βV1M) and test (αV1M βV1M βT84Y) proteins were PEGylated
in the deoxy form using the EURO-PEG-Hb method to prevent rapid
renal clearance [23]. Both proteins were PEGylated at multiple sites
with a slightly enhanced degree of PEGylation in the case of T84Y
(Fig. 8). After PEGylation the measured oxygen affinity increased for
both proteins as expected. However, for T84Y the affinity remained
slightly lower (5.34 ± 0.53 Torr) than for WT (1.70 ± 0.22 Torr),
consistent with what was observed for the unPEGylated mutant
(Table 2).
Fig. 9 shows the whole-body distribution of the labeled proteins
over a 24 h in representative animals along with their organ-level ac-
cumulation. As time progressed, the regional distribution of Cy5-Hb
became heterogeneous depending on the rate of extravasation into the
imaged tissues and organs (Fig. 9A and B). Note that the bladder is seen
as a hot spot on these fluorescent images as all the PEG-Hb molecules
passing through the kidneys accumulated here before excretion in the
urine. Cases of high- and low-accumulations of labeled proteins in
various organs as demonstrated by post mortem direct NIR imaging of
the organs cleared from blood are also demonstrated (Fig. 9C). The
HBOC containing the βT84Y was cleared more slowly (Fig. 9) with a
significantly enhanced vascular retention time (Fig. 10).
Fig. 5. Rate of ascorbate reduction of ferric heme in dif-
ferent mutants. % oxyHb formed after 60min incubation of
following the addition of 100 μM ascorbate to 10 μM metHb
(mean ± SD, n=3). Other conditions as per Fig. 4. Inset
shows lack of correlation between the rate of ferryl (Fig. 3)
and ferric (Fig. 5) heme reduction in the different mutants.
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4. Discussion
4.1. Enhanced ferryl reduction rate
We have shown previously that tyrosine residues can act as redox
centres facilitating the reduction of higher oxidation states of iron in Hb
[16] and in the process decreasing its oxidative reactivity [19]. Our
previous mutation (βF41Y) was at the site in the β subunit, homologous
to where the α subunit already possesses a redox active centre (α42).
We postulated that non homologous sites located in the surface of Hb
and within electron transfer range (< 10 Å) of the heme might have
similar effects or even be superior to the natural and homologous sites
in the relevant subunits. We also predicted that placing the mutation on
the surface and distant from α/β interface should have a minimal effect
on the protein expression, stability and function. From a protein design
viewpoint, the intention is to have minimal effect on Hb other than in
decreasing oxidative reactivity. This would enable the mutation to be
readily incorporated in a HBOC that could then have additional mu-
tations to enhance stability and/or affect other functions, such as de-
creasing nitric oxide scavenging [5]. With one exception this goal was
achieved. The exception was the βK66Y mutation, which could be
readily expressed and purified but was unstable and heterogenous in
the oxidized ferric and ferryl states. So although this mutant had the
fastest ferryl reduction rates, in part this was due to enhanced auto-
reduction to ferric forms that could not be recovered to functional Hb.
This mutation was therefore deemed unstable as a component of a
HBOC and not studied further.
All the other six new mutations in the β subunit showed evidence of
a new redox active centre that could increase ferryl reduction by exo-
genous reductants. There was little effect on reduction at the unaltered
α site, confirming the specificity of the mutations to the subunit in
which they resided. The introduction of a second (non physiological)
tyrosine redox centre in the α subunit (αL91Y) did not seem to greatly
enhance reduction at this site, although there was a modest increase in
the overall rate, possibly via the creation of a new pathway to the β
heme.
In general, although the design decisions were vindicated by the
introduction of these new redox pathways, the overall increase in re-
duction rate was somewhat disappointing. None of the mutations
showed reduction of the β subunit as fast as that present naturally in the
WT α subunit. The engineered proteins were reduced orders of mag-
nitude slower than that observed following the introduction of tyrosine
redox centres into the Aplysia Mb model system [17], despite the fact
that a number of the mutations were engineered to be as homologous as
possible to the relevant Aplysia sites (Table 1). All the natural and en-
gineered mutations are close enough to the heme group (< 10 Å) such
that according to Marcus theory the rate of electron transfer should not
be limited by the nature of the intervening protein medium [32]. In-
deed the fact that introducing tyrosine residues at multiple sites leads to
broadly similar increases in electron transfer rate confirms that the
chemical nature of the electron transfer pathway from tyrosine to heme
is not important.
If the reduced tyrosine radical is formed at 100% occupancy by the
addition of saturating levels of reductant the Vmax value in Table 3
should be on the millisecond, rather the minutes, time scale. We have
previously postulated that the reason for the rather slow electron
transfer rates of ferryl reduction from nearby tyrosine residues was due
to the relevant reactive species only being present in low population
[15]. Thus, the fast intrinsic electron transfer rate (≈ 108 s-1) would
have to be multiplied by a low electron occupancy of the relevant re-
active reduced species to generate the effective rate, the deprotonated
tyrosine radical and the protonated ferryl being the relevant reactive
species. It is possible that the faster rate in Aplysia is therefore due to a
higher intrinsic pK of the protonated ferryl, resulting in a larger po-
pulation of the reactive species. A limitation due to the intrinsic nature
of the ferryl heme in different species/proteins would also explain why
changing the position of the redox active tyrosine in Hb has only a small
effect on the electron transfer rate. However, as even this relatively
modest increase is accompanied by a decrease in lipid peroxidation in
cell free assays [19] the addition of such tyrosine residues would still be
a useful component to an engineered HBOC.
4.2. Enhanced ferric reduction rate
Given the high oxidation potential [12,33] of the ferric/ferryl spe-
cies (≈+ 1V), many mild reductants, both unphysiological such as the
Fig. 6. Ascorbate concentration dependence of ferric heme reduction. Rate
of oxyb Hb formation following the addition of different concentration to
metHb. (a) Time course of reduction at different ascorbate concentrations in
WT Hb. (b) Pseudo first order rate constant as a function of ascorbate con-
centration in selected mutants. Conditions: buffer= sodium phosphate (20mM,
pH 7.20); T= 25 °C; [heme]= 8.75 µM.
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hydroxypyridonones [16,34] and physiological such as urate [9,35]
have the thermodynamic power to readily reduce ferryl to ferric Hb.
However, given the redox potential of ferric/ferrous Hb (≈ -50 to
100mV), stronger reductants are required to further reduce the ferric
species to ferrous. In plasma where HBOC are designed to function, this
is therefore likely limited to glutathione, NADH and ascorbate. The
ascorbate reduction rate is non trivial. Indeed as noted previously [16],
the further conversion of ferric to ferrous Hb by ascorbate can com-
plicate the analysis of the reduction kinetics of ferryl Hb by ascorbate. It
was therefore relevant to test whether the insertion of novel tyrosine
mutations that enhance the conversion of ferryl to ferric Hb, also en-
hanced the conversion of ferric to ferrous Hb.
The ability of ascorbate to reduce directly human met to oxyHb was
first shown in the 1940s [36,37]; this rate was later calculated to be in
the order of 1M-1 s-1 and enhanced by the addition of organic phos-
phates [38,39]. MetMb is also reduced by ascorbate, but a slower
second order rate constant of between 10-3 and 10-2 M-1 s-1 [40]. Glu-
tathione and NADH reduction of metHb is likely to occur at a slower
rate than ascorbate in vivo – this paper and [10,36,41] – especially
given that plasma levels of ascorbate in humans (≈ 50 μM) are sig-
nificantly higher than those of NADH [42] and GSH [43].
A more detailed examination of the ascorbate metHb reduction rate
showed that the reaction proceeded in two stages, with the reduction of
the β being significantly faster than that of the α subunit [28,29], the
latter likely being more akin to that seen in Mb. Consistent with this
fetal Hb, although having a similar reduction potential to adult Hb [44],
lacks a β subunit and has slower reduction kinetics than the adult
protein [20].
The results in this paper significantly enhance our knowledge of the
mechanism of ascorbate reduction of metHb. Fig. 6b shows that in WT
Hb, as ascorbate concentration is varied the reaction obeys second
order kinetics. However, there is a significant positive intercept on the
y-axis. The difficulty of making measurements under pseudo first order
conditions at very low ascorbate concentrations precluded us from a
more detailed analysis. However, we do not feel that this indicates re-
duction occurring at very low or zero ascorbate concentrations and
instead favor an explanation akin to what occurs with ascorbate re-
duction of ferryl Hb. In classical chemical kinetics, a non zero y-axis
intercept could indicate the rate of the reverse reaction, but the as-
corbate reduction of metHb is not readily reversible, especially in the
presence of oxygen which will drag the reaction in the direction of the
ferrous oxy state. Instead the lack of concentration dependence at low
ascorbate (Fig. 6b) likely indicates the saturation of a high affinity (low
μM or less) binding site similar to that seen for the reduction of ferryl
Hb [16]. This is consistent with the original finding by Gibson that
ascorbate reduction at low concentrations is much faster than expected
by second order kinetics [36]. Similar non linear reduction kinetics at
Table 4
Kinetic parameters for ascorbate reduction of ferric Hb mutants. Data
taken from the conditions of Fig. 5 varying ascorbate concentrations from 0.05
to 20mM. The high affinity first order rate constant was taken from the y-axis
intercept (± SEM) of a plot of the pseudo first order rate constant vs ascorbate
concentration. The low affinity (second order) rate constant was calculated
from the slope (± SEM) of a plot of the pseudo first order rate constant at those
higher ascorbate concentrations where there was a clear ascorbate concentra-
tion dependence of the rate (1–20mM).
High affinity rate
(× 10-4 s-1)
Low affinity rate
(× 10-2 M-1 s-1)
WT adult 6.91 ± 0.33 3.16 ± 0.74
βT84Y 37.7a ± 1.2 3.20 ± 0.23
αL91Y 9.28a ± 0.31 3.73 ± 0.85
βF85Y 12.8a ± 0.77 2.06 ± 0.98
βL91E/βL96Y 4.07a ± 0.32 1.66 ± 0.40
WT fetal 1.27a ± 0.17 3.61 ± 0.34
a Significantly different from WT adult as judged by 95% confidence inter-
vals of curve fits.
Table 5
Ferric reduction, heme loss and autoxidation rates of selected mutants.
Conditions: 20mM NaPi (pH 7.2); T=30 °C. Ferric reduction calculated as %
oxy formed 60min after 150 μM ascorbate addition to 5 μM metHb;
Autoxidation rate 10 μM oxyHb; heme loss 1.7 μM metHb. Key: Unpaired t-test
vs relevant control mutation lacking enhanced ferric reducibility.
Ferric reduction
(n=3) % oxy
Autoxidation
(n=6) min-1
Heme Loss
(n=3) min-1
WT 51.5 ± 4.6 0.040 ± 0.010 0.028 ± 0.005
βT84Y 81.7 ± 2.3** 0.036 ± 0.017 0.024 ± 0.003
αL91Y/βT84Y 61.2 ± 1.2* ND ND
αV1M βV1M 21.4 ± 4.3 0.028 ± 0.009 0.032 ± 0.001
αV1M βV1M βT84Y 44.4 ± 1.4*** 0.024 ± 0.008 0.035 ± 0.006
* P < 0.05 vs WT.
** P < 0.005 vs WT.
*** P < 0.005 vs αV1M βV1M.
Fig. 7. Effect of mutations on hemoglobin-induced
cell damage. % oxyHb present 200min after incuba-
tion of 100 μM met or oxy forms of WT and βT84Y to
HEK cells in the presence or absence of 100 μM as-
corbate compared to amount of LDH released 24 h.
There is a significant negative correlation between the
fraction of OxyHb remaining and cell damage. All Hb
used also included the αV1M βV1M mutations.
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lower ascorbate concentrations was also later shown by McGown [45].
Although Gibson attributed the zero order kinetics at low ascorbate to
trace metal contamination in solution, a similar effect in the Hb per-
oxidase kinetics was confirmed by NMR to be due to a specific ascorbate
binding site [46]. The effect of this high affinity binding site is to make
ascorbate reduction of the Hb β subunit at physiological (μM) plasma
ascorbate concentrations as fast as those globins, such as cytoglobin,
which have much faster reduction rates than Hb at higher (mM) as-
corbate [47].
Although the ferric reduction kinetics by ascorbate are similar to the
ferryl reduction kinetics in having a specific high affinity saturable
component and a non specific low affinity component, the under-
pinning mechanisms are different. This is why there is no correlation
between those mutants that enhance ferryl reducibility and those that
enhance ferric reducibility (Fig. 5). Table 4 shows that there is no effect
of inserting tyrosine residues on the low affinity rate. Nor is this rate
different in adult and fetal Hb. The calculated range of low affinity rates
(1–4× 10-2 M-1 s-1) is consistent with that previously reported for
metMb and therefore likely relates to the direct second order reduction
of the heme by ascorbate. A more positive heme redox potential was
Fig. 8. PEGylation efficiency of mutations. The fraction of conjugated PEG chains per tetramer was evaluated by a probabilistic calculation from the distribution of
PEGylated monomers obtained by SDS PAGE.
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postulated to underpin an enhanced reducibility of the ferric heme in
Lumbricus Hb [41]. The similarity of the direct low affinity ascorbate
reduction rates for WT Hb, fetal Hb and our adult Hb mutants suggest
that this effect is not present here.
The faster rates at low ascorbate concentrations are likely caused by
the specific ascorbate binding site on the β subunit. The addition of
tyrosine residues that decrease this rate (βF41Y, βK66Y, βF71Y, βL91E/
βL96Y) might act via minor structural changes to the protein perturbing
the ascorbate binding site. Mutations that increase this rate (βT84Y,
αL91Y, βF85Y) might also act on the binding site, but it is equally
possible that they enable an additional electron transfer pathway from
the ascorbate binding site to the β or even the α heme. This seems
especially likely for the α subunit mutation (αL91Y) and the β mutation
that has the fastest rate of electron transfer (βT84Y).
4.3. In vivo studies
We have previously demonstrated that engineered human HBOC
with an increased reducibility of ferryl Hb by physiological plasma
reductants decrease Hb-induced oxidative stress [19]. The increased
reducibility of ferric to ferrous Hb found in the multimeric Hb (ery-
throcruorin) in earthworms (Lumbricus) has also been promoted as a
benefit of HBOC [41]. βT84Y has both these positive features, is no
worse than WT Hb in terms of autoxidation and heme loss (Table 5)
and, in the presence of ascorbate, maintained Hb in the oxy state de-
creasing cell damage (Fig. 7). We therefore chose it as a component of a
HBOC that would decrease oxidative stress and remain longer in the
functional ferrous state in vivo. Converting Hb into a HBOC requires
increasing the effective size of the dimer to prevent premature renal
clearance via cross-linking, polymerization or conjugation. We chose to
PEGylate βT84Y in the deoxy state using the EURO-PEG-Hb method as
this has been shown to have advantages over PEGylation in the oxy
state, such as decreased tendency to dimerization [48]. PEGylation was
successful; the oxygen affinity of PEGylated βT84Y (≈ 5 Torr) was si-
milar to that in the Sangart HBOC product, MP4, proposed to facilitate
oxygen transfer from the red blood cell to hypoxic tissues [11].
PEG-Hb labeling studies showed the PEGylated proteins had a
plasma half time of several days (Figs. 9 and 10), in agreement with our
own [23] and other such products that have been tested [49] and ideal
for an oxygen therapeutic product used in acute clinical settings. There
have been relatively few studies on tissue uptake of PEG-Hb and none in
a mouse model. In a rat model Bovine PEG-Hb showed accumulation in
the liver and kidneys and an intravascular half-life of 17–19 h com-
parable to our findings shown in Figs. 9 and 10 [50,51]. In a mouse
model [52] the uptake of PEGylated nanoparticles containing Hb also
found high retention in liver and kidneys and low retention in heart,
spleen and bone, again consistent with our data.
The βT84Y product was more PEGylated (Fig. 8) than WT and had
an enhanced vascular retention time (Figs. 9 and 10). PEGylation dif-
ferences may be partly responsible for the enhanced retention. How-
ever, the βT84Y product is more readily reducible. Heme loss is en-
hanced from the ferric state of Hb [18] and a protein with no heme is
likely to be cleared more quickly than ferrous Hb. Increased vascular
retention time can also be due to a decrease in oxidative stress caused
by the T84Y mutant [53] as oxidative stress could increase vascular
escape via a damaged endothelial layer [54]. Alternatively a direct
explanation is possible if the surface charge of the protein is modified as
permeability is decreased the more negative the surface charge [23,55]
Future studies will be needed to determine if this vascular enhancement
was a function of the more effective PEGylation, modification to the
protein surface charge, enhanced ascorbate reducibility or and/or de-
creased oxidative stress.
5. Conclusion
Ascorbate has been shown to be the key plasma antioxidant for
HBOC, maintaining it in the ferrous state and reducing oxidative species
such as ferryl and protein free radicals [9,10,56]. Key to this is the
ability of the erythrocyte transmembrane reductase system to use in-
tracellular ascorbate as a reductant for the oxidized ascorbate radical in
plasma, maintaining levels of the reduced species [10,45,57,58]. When
these are compromised in vivo, for example in species such as humans
and guinea pigs that lack the ability to synthesis ascorbate de novo,
HBOC cause increased oxidative stress [9,56]. The results in this paper
show that Hb has a high affinity ascorbate binding site such that the
rate of both ferryl and ferric reduction is not significantly compromised
until ascorbate levels fall significantly below normal plasma levels. It is
also possible to engineer mutations to enhance the reducibility of Hb in
a HBOC. Mutations that incorporate these features, such as βT84Y, may
therefore be useful as components of a less oxidatively damaging
HBOC, which has increased vascular retention. Knowledge of the
Fig. 9. In vivo whole-body distribution of PEGylated Hb. Top: NIR scans
shown for various time points up to 24 h following top-load infusion of WT
(αV1M βV1M) and T84Y (αV1M βV1M βT84Y) PEG-Hb conjugated to the
Lumiprobe Cy5. Raw intensity data are displayed in arbitrary pseudo-color
scale of fluorescence intensity. Note the negligible autofluorescence of the an-
imal (far right). Bottom: Ex vivo organ-specific direct NIR fluorescence imaging
for accumulation of Cy5-labeled WT PEG-Hb.
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position and structure of the ascorbate binding site in the β subunit will
possibly enable future mutants with engineered electron transfer
pathways from this site to the α subunit heme or, more speculatively,
incorporate an additional binding site into the adult α and/or fetal γ
subunits.
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